IceCure Reports Resounding Success Destroying Tumors With Ice In Breast Cancer Trial
NoCamels Team | May, 6 2018
This article was re-published with permission from NoCamels.com – Israeli Innovation News.
IceCure Medical, a Caesarea-based biomedical company that developed technology which turns cancerous tumors into ice balls, reported this week that clinical trials across the US were showing initial success of to 99 percent.
Founded in 2006, IceCure has advanced the concept of cryoablation, a process which uses extreme cold to freeze and destroy diseased tissue used by medical experts for years, to develop technology that coule be applied to cancer tumors. In 2012, using the company’s IceSense3 system, a minimally invasive cryoablation treatment for breast disease in a non-surgical manner, doctors treated benign breast cancer tumors in four patients during a clinical trial conducted in Kamogowa, Japan. The system had specifically been developed to treat fibroadenomas, which are the most common type of benign breast tumors, typically seen in young women aged 15 to 30.
Now, IceCure is looking at initial results from what it called its “biggest clinical trial” thus far, involving 18 hospitals and medical centers across the US including Columbia University Medical Center and Mount Sinai Beth Israel, both in New York.
Using the IceSense3 system, IceCure said doctors performed the procedures on 146 patients, a majority (103) of whom were under monitoring for almost two years. The company reported that out of the 146 women, one saw the cancer recur.
The patients in this recent trial were all older women, with an average age of 76, affected by early-stage breast cancer. The tumors treated were no bigger than 1.5 centimeters in circumference, IceCure said in a statement.
To continue reading this article on NoCamels.com, click here.